Nonselective β‐blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients

Lars Bossen, Aleksander Krag, Hendrik Vilstrup, Hugh Watson, Peter Jepsen – 24 November 2015 – The safety of nonselective β‐blockers (NSBBs) in advanced cirrhosis has been questioned. We used data from three satavaptan trials to examine whether NSBBs increase mortality in cirrhosis patients with ascites. The trials were conducted in 2006‐2008 and included 1198 cirrhosis patients with ascites followed for 1 year.

Recipient aging accelerates acquired transthyretin amyloidosis after domino liver transplantation

Yohei Misumi, Yasuko Narita, Toshinori Oshima, Mitsuharu Ueda, Taro Yamashita, Masayoshi Tasaki, Konen Obayashi, Kaori Isono, Yukihiro Inomata, Yukio Ando – 24 November 2015 – Domino liver transplantation (DLT) with liver grafts from patients with hereditary transthyretin (TTR) amyloidosis has been performed throughout the world because of a severe liver graft shortage. Reports of acquired systemic TTR amyloidosis in domino liver recipients have been increasing; however, the precise pathogenesis and clinical course of acquired TTR amyloidosis remains unclear.

Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof‐of‐concept study

Gideon M. Hirschfield, M. Eric Gershwin, Richard Strauss, Marlyn J. Mayo, Cynthia Levy, Bin Zou, Jewel Johanns, Ivo P. Nnane, Bidisha Dasgupta, Katherine Li, Carlo Selmi, Hanns‐Ulrich Marschall, David Jones, Keith Lindor, PURIFI Study Group – 24 November 2015 – The interleukin (IL)‐12 signaling cascade has been associated with primary biliary cholangitis (PBC).

Flushing the liver with urokinase before transplantation does not prevent nonanastomotic biliary strictures

Lars C. Pietersen, A. Claire Dulk, Andries E. Braat, Hein Putter, Kerem Sebib Korkmaz, Andre G. Baranski, Alexander F. M. Schaapherder, Jeroen Dubbeld, Bart Hoek, Jan Ringers – 24 November 2015 – The aim of the present study was to assess whether flushing the donor liver with urokinase immediately before implantation reduces the incidence of nonanastomotic biliary strictures (NASs) after liver transplantation, without causing increased blood loss, analyzed as a historical cohort study. Between January 2005 and October 2012, all liver (re‐)transplantations were included.

Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study

Fabio Piscaglia, Gianluca Svegliati‐Baroni, Andrea Barchetti, Anna Pecorelli, Sara Marinelli, Claudio Tiribelli, Stefano Bellentani, HCC‐NAFLD Italian Study Group – 24 November 2015 – Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome and may evolve into hepatocellular carcinoma (HCC). Only scanty clinical information is available on HCC in NAFLD.

The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota

Jérôme Boursier, Olaf Mueller, Matthieu Barret, Mariana Machado, Lionel Fizanne, Felix Araujo‐Perez, Cynthia D. Guy, Patrick C. Seed, John F. Rawls, Lawrence A. David, Gilles Hunault, Frédéric Oberti, Paul Calès, Anna Mae Diehl – 24 November 2015 – Several animal studies have emphasized the role of gut microbiota in nonalcoholic fatty liver disease (NAFLD). However, data about gut dysbiosis in human NAFLD remain scarce in the literature, especially studies including the whole spectrum of NAFLD lesions.

Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR‐148a on tumor growth and phenotype and liver fibrosis

Kwang Hwa Jung, Jing Zhang, Chong Zhou, Hong Shen, Mihai Gagea, Cristian Rodriguez‐Aguayo, Gabriel Lopez‐Berestein, Anil K. Sood, Laura Beretta – 24 November 2015 – The death rate from hepatocellular carcinoma (HCC) is increasing, and liver cancer is the second leading cause of cancer‐related mortality worldwide. Most patients with HCC have underlying liver cirrhosis and compromised liver function, limiting treatment options. Cirrhosis is associated with cell dedifferentiation and expansion of hepatocholangiolar progenitor cells.

Subscribe to